MISSION“A new step to jump
toward a global
In January 2019, ILIAS Therapeutics, Inc.
was established as wholly owned subsidary of ILIAS Biologics Inc.
ILIAS Therapeutics is expanding to develop novel exosome-based
therapeutics in the global market. To be a global pharmaceutical
company, we will collaborate with various research institutions and
build a sustainable business management system in the U.S.
ILIAS Therapeutics, Inc.
Jamie Kim, MS
Chairman of the board
Chulhee Choi MD, PhD
January 22, 2019